Magnetic field-controlled gene expression in encapsulated cells  by Ortner, Viktoria et al.
Journal of Controlled Release 158 (2012) 424–432
Contents lists available at SciVerse ScienceDirect
Journal of Controlled Release
j ourna l homepage: www.e lsev ie r .com/ locate / jconre lMagnetic ﬁeld-controlled gene expression in encapsulated cells
Viktoria Ortner a,b,1, Cornelius Kaspar c,1, Christian Halter d, Lars Töllner c,2, Olga Mykhaylyk e,
Johann Walzer d, Walter H. Günzburg c,f, John A. Dangerﬁeld c,f,g, Christine Hohenadl c, Thomas Czerny a,b,⁎
a University of Applied Sciences, FH Campus Wien, Department for Applied Life Sciences, Helmut-Qualtinger-Gasse 2, A-1030 Vienna, Austria
b Department for Biomedical Sciences, University of Veterinary Medicine, Veterinärplatz 1, A-1210 Vienna, Austria
c Department for Pathobiology, Institute of Virology, University of Veterinary Medicine, Veterinärplatz 1, A-1210 Vienna, Austria
d University of Applied Sciences, FH Campus Wien, Department for Engineering, Favoritenstrasse 226, A-1100 Vienna, Austria
e Department for Pathobiology, Institute for Experimental Oncology, Klinikum Rechts der Isar, TU Munich, Ismaninger Strasse 22, 81675 Munich, Germany
f Christian Doppler Laboratory for Gene Therapeutic Vector Development, Institute of Virology, University of Veterinary Medicine, Veterinärplatz 1, A-1210 Vienna, Austria
g SG Austria, 20 Biopolis Way, Centros #05-518, 138668, Singapore⁎ Corresponding author at: University of Applied Scien
ment for Applied Life Sciences, Helmut-Qualtinger-Ga
Tel.: +43 1 606 68 77 3511.
E-mail address: thomas.czerny@fh-campuswien.ac.a
1 These authors contributed equally to this work.
2 Present address: ACIB, Muthgasse 11, A-1190 Vienn
doi:10.1016/j.jconrel.2011.12.006
0168-3659 © 2011 Elsevier B.V. Open access under CC BY-a b s t r a c ta r t i c l e i n f oArticle history:
Received 6 October 2011
Accepted 7 December 2011
Available online 16 December 2011
Keywords:
Magnetic nanoparticles
Hyperthermia
Inducible gene expression
Cell encapsulation
Cell therapy
Gene therapyCell and gene therapies have an enormous range of potential applications, but as formost other therapies, dosing is
a critical issue, which makes regulated gene expression a prerequisite for advanced strategies. Several inducible
expression systems have been established, which mainly rely on small molecules as inducers, such as hormones
or antibiotics. The application of these inducers is difﬁcult to control and the effects on gene regulation are slow.
Here we describe a novel system for induction of gene expression in encapsulated cells. This involves the
modiﬁcation of cells to express potential therapeutic genes under the control of a heat inducible promoter and
the co-encapsulation of these cellswithmagnetic nanoparticles. These nanoparticles produce heatwhen subjected
to an alternatingmagneticﬁeld; the elevated temperatures in the capsules then induce gene expression. In the pre-
sent study we deﬁne the parameters of such systems and provide proof-of-principle using reporter gene con-
structs. The ﬁne-tuned heating of nanoparticles in the magnetic ﬁeld allows regulation of gene expression from
the outside over a broad range and within short time. Such a system has great potential for advancement of cell
and gene therapy approaches.
© 2011 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Most human diseases are based on the absence, misexpression or
deregulation of gene products. Gene therapy is an approach to transfer
DNA encoding therapeutic proteins into the patient to modulate the
pathologic cellular pathways. Depending on the vector, transient
expression or stable integration of the constructs is achieved.
Integration into the host's genome results in long term production of
the therapeutic protein, although random integration can result in
severe problems (reviewed in Ref. [1]). Cell therapy represents a
different approach, which is based on transplantation of cells producing
the therapeutic protein. The classic approach has been to use
autologous cells (reviewed in Ref. [2]); however, heterologous cells
would have no limitation in their availability or for theirmanufacturing,
i.e. in contrast to autologous products, would allow an off-the-shelf
product to be generated. One limitation is however, that heterologousces, FH CampusWien, Depart-
sse 2, A-1030 Vienna, Austria.
t (T. Czerny).
a, Austria.
NC-ND license.cells activate the immune system of the patient, which rapidly destroys
them. To avoid this, microencapsulation can be used, as the semiperme-
able membrane protects the cells from the immune response. This
allows their prolonged survival in vivo, making cell therapy one of the
most exciting ﬁelds of translational medicine [3]. This approach has
been shown to be viable in human clinical trials and it has also been
demonstrated that such encapsulated cell products can be GMP
manufactured at large scale [4,5].
Cell and gene therapies promise a wide range of applications in
biomedicine. Similar to small molecules, also the effects of biologicals
strongly depend on the dosage. Regulated expression therefore is
essential for such strategies. In the last 20 years several inducible
expression systems have been established, such as the tetracycline
(TetR)-inducible system (reviewed in Ref. [6]) or the progesterone
receptor/mifepristone (RU486)-inducible system [7]. These induction
systems act via small activator molecules that are generally orally
administered. However, the slow pharmacokinetics of these activators
strongly limit the regulation of such systems in vivo. In contrast, one
component systems use endogenous activation pathways and
transcription factors. Most successful within this group are promoters
reacting to the heat shock response.
The heat shock response represents the most important stress
survival pathway of the cell. After exposure to different kinds of
425V. Ortner et al. / Journal of Controlled Release 158 (2012) 424–432stress, like heat, heavy metals or radiation, heat shock factor 1 (HSF1),
a key mediator of the pathway, is activated in the cytoplasm. It trans-
locates to the nucleus where it binds to the heat shock elements
(HSE), speciﬁc DNA motifs in the promoters of stress pathway-
related genes (reviewed in Ref. [8]). Most of these genes encode
heat shock proteins (HSP), which are acting as chaperones to prevent
aggregation of denatured or partially unfolded proteins. Heat shock
promoter regions show a complex architecture and integrate inputs
from several different cellular pathways, limiting their application in
therapeutic approaches. Consequently, modiﬁed natural promoters
have been established (reviewed in Ref. [9]), showing low
background activity and high inducibility. Activation is achieved by
elevated temperatures, which can be provoked by external manipula-
tion. Local hyperthermia, for example, can be induced by magnetic
nanoparticles (NP) exposed to an alternating magnetic ﬁeld (AMF).
The magnetic cores of these NPs have a size in the nanometer range
and are mainly composed of magnetite (Fe3O4), maghemite (γ-
Fe2O3) or Co/Mn iron combinations [10]. By applying an AMF, a
constant ﬂow of energy is established in NPs, which is then trans-
ferred into thermal energy (reviewed in Ref. [11]). Biocompatibility
of iron oxide NPs is largely affected by the coating [12–14], allowing
different biomedical applications such as cancer treatment [15],
gene transfer by magnetofection [16,17], targeted drug delivery [18]
or their use in magnetic resonance imaging and related diagnostic
techniques [19]. However, iron oxide NPs can also exhibit harmful
properties and therefore surface coating, cellular targeting, and local
exposure have to be considered for clinical applications [20].
In this work, we combined NP-mediated hyperthermia with a cell
therapy approach. By co-encapsulating cells and NPs, the AMF-
induced heat generation is restricted to the encapsulated cells,
which contain the heat-inducible gene expression construct. With
this concept we demonstrate highly regulated expression of two
reporter genes in cells co-encapsulated with magnetic NPs in
response to AMF treatment.
2. Materials and methods
2.1. Plasmids
The vector pSGH2luc [21] was used for expression of the reporter
genes ﬁreﬂy luciferase (luc) and green ﬂuorescent protein (GFP).
Expression was driven by an artiﬁcial heat shock-inducible promoter
composed of a core of eight idealised HSEs ﬂanked by two minimal
cytomegalovirus (CMV) promoter elements. To facilitate establishment
of stably transfected cell clones, a puromycin resistance gene cassette
was introduced into the construct (pSGH2luc puro).
2.2. Cell culture
For generation of a stable cell line, HEK293 cells were transfected
with the pSGH2luc puro construct using polyethyleneimine (PEI) as a
transfection reagent. Stable cell clones were selected with 1 μg/ml
puromycin. HEK293 cells constitutively expressing luc or GFP were
generated by transfection with CMV promoter-driven expression
vectors pCMVluc and pCMVGFP [22]. All cells were grown in Dulbecco's
modiﬁed Eagle's medium (DMEM), supplemented with 10% fetal calf
serum (FCS), 100 U/ml penicillin and 100 U/ml streptomycin at 37 °C
and 5% CO2.
2.3. Cell viability assays
The effect of heat treatment on cell survival was determined
applying a trypan blue assay. Brieﬂy, 24 hours after heat treatment,
detached cells contained in the culture medium as well as the trypsi-
nated cell layer were collected by centrifugation (5 min and 116g)
and resuspended in 1 ml PBS. 50 μl of the cell suspension was mixedwith an equal volume of a 0.5% trypan blue solution and incubated for
2 min at room temperature. The percentage of dead cells was
determined microscopically by counting the number of blue cells
compared to the number of total cells using a haemocytometer.
For the analysis of the metabolic activity of encapsulated cells, an
AlamarBlue assay (AbD Serotec) was performed. Metabolically active
cells are able to convert the AlamarBlue substrate into resoruﬁn,
which can be quantiﬁed ﬂuorometrically. Therefore, a deﬁned number
of capsules (n=10) was pipetted in triplicates into a black 96-well
plate. Wells containing the respective cell culture medium served as a
sample blank. AlamarBlue reagent was pipetted into all samples and
blanks. Plates were then incubated in a cell culture incubator at 37 °C
(5% CO2, 95% relative humidity) for 4 hours and subsequently analysed
using a ﬂuorometric plate reader (Tecan Genios™, excitation 520 nm
and emission 590 nm). Different dilutions (37.5 μM, 12.5 μM, 4.17 μM
1.39 μM, 0.463 μM and 0.154 μM) of resuroﬁn were used as positive
control. The number of viable encapsulated cells was calculated
according to a standard curve prepared with a given amount of non-
encapsulated cells.
2.4. Heat induction
A deﬁned number of cells was seeded into cell culture dishes and
cultivated for 3 days at 37 °C. For induction of gene expression by heat
treatment, cells were transferred to a cell culture incubator pre-
adjusted to 43 °C (except experiments in Fig. 2 where the incubator
was adjusted to 41 °C, 42 °C, 43 °C or 44 °C). To ensure an optimal
temperature transfer, the cell culture plateswere placed onmetal plates
kept in the incubator. After heat treatment for 0.5–2 hours, cells were
transferred back to 37 °C and incubated further (up to 6 hours) to
allow recovery.
2.5. Reporter protein assay
To determine the activity of the expressed luciferase, cells or
capsules were lysed in 50–100 μl luciferase lysis buffer (0.1 M Tris
pH 7.5, 1% Triton X and 1 mM DTT); capsules were mechanically
destroyed using a pestle and all samples were incubated for 15 min
at room temperature. Samples were centrifuged for 5 min at 94g
and all of the cleared cell lysate was used for a luciferase activity
measurement in a LUMAT LB luminometer (Berthold).
GFP expression was analysed by ﬂow cytometry (FACS Calibur, BD
Biosciences). A proprietary method was used to dissolve the capsules.
For this purpose 140 capsules at a time were mixed with 5× weight/
volume of dissolving solution and shaken at 37 degrees for 1 hour.
Then cell culture medium was added and the cells were plated out.
The analysis by quantitative ﬂow cytometry is described in Ref. [23].
GFP levels were determined by combining the number of gated cells
with their mean ﬂuorescence intensity. Relative induction was then
calculated by comparing the GFP levels of induced versus non-
induced samples.
2.6. Quantitative real-time PCR
To analyse reporter gene mRNA expression levels after heat stress,
cells were incubated for different time spans at 43 °C and lysed either
directly or after up to 48 hours of recovery at 37 °C. Total RNA was
isolated according to the manufacturer's protocol using an RNA
extraction Kit (Invisorb). Residual DNA was removed with DNAse I
(Fermentas) and the mRNA was transcribed into cDNA (RevertAid™
H Minus First Strand cDNA Synthesis Kit, Fermentas) using random
hexamer primers according to the manufactures protocol. For qPCR,
Taqman probes were designed using Primer Express V2 (Applied
Biosystems) and the cDNAwas ampliﬁed in an Mx3000P (Stratagene)
qPCR cycler. The human glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) gene was used as an endogenous control. The following
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GGA AGG TGA AGG TCG GAG TCA A-3′, reverse: 5′-ACC AGA GTT
AAA AGC AGC CCT G-3′, probe: 5′-HEX-ATT TGG TCG TAT TGG GCG
CCT GGT C-BHQ1-3′; luciferase forward: 5′-TGG ATT ACG TCG CCA
GTC AAG-3′, reverse: 5′-TTC GGT ACT TCG TCC ACA AAC A-3′,
probe: 5′-Fam-CGC GAA AAG TTG CGC GGA GG-BHQ1-3′; Hsp72
forward: 5′-AAC CAG GTG GCG CTG AAC-3′, reverse: 5′-TGG AAA
GGC CAG TGC TTC AT-3′, probe: 5′-Fam-AAC ACC GTG TTT GAC GCG
AAG CG-BHQ1-3′; for GFP primers and probes see Ref. [24]. The
expression levels of luciferase, GFP or Hsp72 were normalised to the
expression levels of GAPDH.
2.7. Magnetic NPs
13 Different types of iron oxide NPs were tested for the efﬁciency of
heat production. Additionally one commercially available formulation
from Sigma-Aldrich (Iron(II,III)oxide nanopowder 98+%, Cat. No.
637106-25G) was used. All NPs were composed of a magnetic iron
oxide core of different diameters (Supplementary Table S1). The
particles S1, S7, and S8 with a core diameter from 30 to 80 nm were
synthesised using oxidative hydrolysis method according to the
procedure of Sugimoto and Matiievic [25] based on the precipitation
of iron (II) salts in basic media and in the presence of nitrate ions as a
mild oxidant, followed by addition of the coating component (palmitoyl
dextran or branched polyethyleneimine 25 kDa). The particles with
smaller average core diameter of 4 to 13 nm were synthesised by
precipitation of Fe(II)/Fe(III) hydroxide by transformation into magne-
tite in an oxygen-free atmospherewith spontaneous adsorption of shell
components as described elsewhere [16,26,27]. Composition of the
particle coatings is given in Table S1.
2.8. Magnetic ﬁeld induction
The magnetic ﬁeld generator consisted of a power supply, a
frequency generator and a power ampliﬁer generating up to 27 A at
60 kHz. For measurements, an oscilloscope and a frequency counter
were connected. The strength of the alternating magnetic ﬁeld
(AMF) generated in the middle of the induction coil was measured
at 36 kA/m (at 27 A and 60 kHz). The induction coil was built from
brass tubes permanently cooled using deionised water (20 °C). For
the experiments without capsules, a similar coil with an additional
water jacket around the reaction tube was used to further reduce
heating of the samples (resulting magnetic ﬁeld strength 33 kA/m at
27 A and 60 kHz).
To determine the activation of gene expression in response to AMF
treatment, 105 cells mixed with 0.5% (w/v) magnetic NPs or 140
capsules containing approximately 3.5×105cells (≈2500 cells/capsule)
either co-encapsulatedwith 0.5%magnetic NPs S8 or containing noNPs,
were transferred with 200 μl of culture medium into a reaction tube
(Eppendorf), pre-incubated at 37 °C and then placed into the induction
coil for 30 min. Immediately after treatment, cells or capsules were
removed from the coil, supplied with 2 ml medium and transferred to
37 °C for recovery. Luciferase activity was determined 6 hours after
end of induction.
2.9. Encapsulation
For encapsulation, the IE-50R device from Inotech was employed,
facilitating vibration-induced drop formation of a viscous polymer
solution in a laminar jet. Cells and NPs were encapsulated using the
biologically inert polyanion sodium cellulose sulphate (SCS, Fraunhofer,
Potsdam) as amatrix. Capsule formationwas enabled by gelating SCS in
a solution of polycationic poly-diallyl dimethyl ammonium chloride
(pDADMAC, Kaptol Chemie) according to the procedure initially
described by Dautzenberg et al. [28]. For standard encapsulation
experiments, 106 cells/ml in phosphate-buffered saline (PBS) weremixed with 1.8% SCS. Co-encapsulation of cells with 0.5% magnetic
NPs S8 was performed with 1.6% SCS. For gel formation, a solution of
1.3% pDADMAC (24 kDa) was used.
2.10. Histology
In order to analyse effects of magnetic ﬁeld treatment on cell
viability and integrity, encapsulated cells were ﬁxed in pre-chilled
(4 °C) 2% formalin in PBS for 1 hour at room temperature (RT).
Subsequently, capsules were embedded in HistoGel (Richard-Allan
Scientiﬁc) according to the manufacturer's instructions, with the
exception that samples were allowed to cool for 3 hours at 4 °C.
Then samples were dehydrated over night by incubation in an
ascending series of ethanol using an automatic device (Thermo
Scientiﬁc). The next day, samples were embedded in parafﬁn. Parafﬁn
blocks were sectioned in 3 μm thick sections using a microtome
(RM2235, Leica).
For further evaluation, sections were deparafﬁnised and rehydrated
and either stained with hematoxylin/eosin or subjected to a TUNEL
assay (ApoTagR Red In Situ, Chemicon) according to manufacturer's
instructions to determine the amount of apoptotic cells. Brieﬂy, sections
were incubated with digoxygenin-labelled nucleotides, which were
transferred onto free 3′OH-termini of DNA present in apoptotic nuclei
by a TdT-enzyme and subsequently incorporated digoxigenin-labelled
nucleotides were detected by rhodamin-labelled antibodies. Finally,
nuclei of encapsulated cells were counterstained with DAPI. For
microscopic examination, samples were dehydrated by incubation in
an ascending series of ethanol followed by incubation in xylol, ﬁnally
mounted with DPX resin and covered with a cover slip.
For transmission electron microscopy (TEM), samples were ﬁxed
with 3% glutaraldehyde for at least 2 days. Subsequently, samples
were washed three times with Soerensen buffer (pH=7.4, 0.1 MNa2-
HPO4 and KH2PO4) for 15 min followed by incubation in 1% osmium
in Soerensen buffer for 2 hours. After washing, encapsulated cells
were dehydrated in an ascending ethanol series, i.e., in 30% for
5 min, 50% for 5 min, 70% for 60 min, twice in 80% 15 min each,
twice in 96% ethanol for 15 min each, and twice in 96% (analysis
grade) for 20 min each. Pure propylene oxide was added to the
samples for 10 min twice and then a mixture of propylene and resin
1:1 was added for 60 min. Subsequently samples were put into a
mixture of propylene and resin at a concentration ratio of 1:3 over
night. The next day, samples were incubated in freshly prepared
resin for 2 hours. Samples were allowed to polymerise by incubation
at 60 °C for 3 days. Polymerised samples were cut using an ultratome
(Ultracut S, Richard) into 100 nm thin sections, which were ﬁxed on a
copper grid (Plano). Samples were stained with uranyl acetate (2% in
80% methanol) for 8 min, washed three times for 10 s in ddH2O,
incubated in lead citrate for 5.5 min and subsequently washed three
times for 10 s in ddH2O.
3. Results
3.1. Experimental concept
As outlined in Fig. 1, the intention of our experiments was to
combine encapsulation of cells with an efﬁcient induction system.
To enable full control from the outside, a heat shock-inducible system
(Fig. 1a) was selected to regulate expression of reporter genes in
genetically modiﬁed cells. After encapsulation of these cells together
with magnetic NPs (Fig. 1b, c), heat can be induced within the
capsules by applying an external AMF (Fig. 1d). Proof-of-principle is
provided by successful activation of reporter gene expression in
encapsulated cells. In possible clinical applications, capsules with
cells containing therapeutic genes may be transplanted into human
tissue and similarly activated by an external magnetic ﬁeld (Fig. 1e).
Fig. 2. Determination of optimal heat shock conditions for HSE promoter-driven
expression. (a) The HEK293-C5 stable cell line was incubated at 41–44 °C for 1 hour
to induce a heat shock response and luciferase activity was determined 6 hours after
heat treatment. The luciferase activity levels were normalised to the values measured
in the cells incubated at 37 °C. (b) To analyse cell viability, cells were prepared and
heat-treated as described in (a). 24 hours after heat treatment, cells were stained
with trypan blue and the percentage of viable cells was determined. Both experiments
were performed in sextuplets; error bars: mean±SEM, n=6.
Fig. 1. Schematic representation of the suggested therapeutic concept. A human cell
line is generated containing the artiﬁcial, inducible heat shock promoter construct
(a). Cells are then encapsulated together with magnetic nanoparticles (NP) (b, c).
The permeable capsule membrane protects encapsulated cells from being attacked by
the host's immune system (c). Application of an alternating magnetic ﬁeld (AMF) ex-
cites co-encapsulated NPs resulting in elevated temperatures within the capsules,
thereby inducing expression in encapsulated cells (d). Consequently, expression of a
therapeutic gene within implanted capsules can be regulated from the outside, a con-
cept which might be used as a new therapeutic strategy for cell therapy in humans (e).
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possible, according to the speciﬁc requirements of the therapy.
3.2. Characterisation of the heat-inducible cell line
In a ﬁrst step, a stable cell line was generated harbouring a heat-
inducible promoter construct. For generation of the vector construct,
a bidirectional artiﬁcial heat shock promoter containing multimerised
heat shock elements (HSE) ﬂanked by minimal promoter sequences
was used. This promoter has been shown previously to be highly
inducible with an extremely low background activity [21]. The
bidirectional activity of the promoter was applied to simultaneously
express luciferase and GFP. The construct was stably integrated into
human embryonic kidney (HEK) 293 cells. A cell clone (C5) was
selected, which showed the lowest background activity combined
with a high inducibility of the artiﬁcial promoter. To test its inducibility
in more detail, the cell clone was incubated for 1 hour at different
temperatures and luciferase activity was measured 6 hours later
(Fig. 2a). Atmild heat shock conditions (41–42 °C) low levels of luciferase
expression were detected, while a more than 2800-fold induction of
luciferase expression was shown after incubation at 43 °C. The level of
induction further increased to ~7000-fold for 44 °C (Fig. 2a). In parallel
to luciferase measurements also survival rates of heat-treated cells
were determined. At lower heat shock temperatures, i.e., 41 °C and
42 °C, cell viability (~95% living cells) did not signiﬁcantly differ from
the cells incubated at 37 °C. The percentage of living cells however
decreased to 93.5% in samples incubated for 1 hour at 43 °C and dropped
further to 91.5% after incubation at 44 °C (Fig. 2b). Consequently, 43 °C
was chosen for the following heat shock experiments as an optimal
compromise between high promoter inducibility and good survival rates.
For the application in regulated gene expression approaches, the
kinetics of this inducible promoter in response to heat treatment
was determined. Therefore, cells were incubated at 43 °C for different
time spans (0.5, 1 and 2 hours) and protein and RNA levels were
investigated at several time points (0.5 to 48 hours) thereafter
(Fig. 3). Luciferase activity steadily increased within 2 hours, reaching
a peak level between 4 and 6 hours depending on the duration of the
exerted stress (reduced durations of heat treatment resulted in a shift
of peak activity to earlier time points). Thereafter, luciferase activity
continuously decreased to almost basal levels after 48 hours
(Fig. 3a). Promoter kinetics in addition were analysed at the level of
mRNA to exclude effects of protein stability (Fig. 3b). In cells thathad been incubated for 30 min at 43 °C, maximum luciferase mRNA
levelswere detected 2 hours after heat treatment. After prolonged incu-
bation (1–2 hours), luciferase mRNA revealed peak levels after 4 hours
(Fig. 3b). The kinetics of luciferase mRNA did however not closely
resemble that of luciferase activity, in particular effects of the various
heat exposure times were more pronounced for the mRNA. To see
whether these differences are based on effects of heat exposure at the
protein level, we also determined the kinetics of the GFP mRNA,
which appeared to be more stable, resulting in extended high levels
up to 12 hours after heat treatment (Fig. 3c). The GFP mRNA kinetics
closely resembled that of luciferase activity, indicating that the various
exposure times did not differentially affect translation or protein
stability of luciferase protein. These data clearly demonstrated
functionality of the artiﬁcial bidirectional heat-inducible promoter and
a regulation at the transcriptional level.
To compare the expression kinetics of the artiﬁcial promoter to
the natural heat shock response, endogenous Hsp72 expression was
investigated (Fig. 3d). Hsp72 mRNA was activated at lower levels,
but with similar kinetics as the reporter gene mRNA was initiated by
the artiﬁcial promoter. Interestingly, between 6 and 12 hours the
Hsp72 mRNA level dropped below that of untreated cells (37 °C
control). This repression might be due to a negative feed-back
regulation exerted by HSPs [29], which does not affect the artiﬁcial
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Fig. 3. Kinetics of the heat shock response in HEK293-C5 cells. HEK293-C5 cells were in-
cubated at 43 °C to induce a heat shock response and protein activity (a) or mRNA levels
(b–d) were measured at different time points (0.5–48 hours) after treatment. (a) Lucifer-
ase activity was measured and normalised to the corresponding levels (set to 1) of cells
incubated at 37 °C. These basal levels were only slightly above the background light
units of the luminometer, indicating an extreme low background activity of the promoter.
(b–d) mRNA was isolated, transcribed into cDNA and speciﬁc amounts of luciferase-
encoding mRNA (b), GFP-encoding mRNA (c), or endogenous Hsp72-encoding RNA (d)
were determined by quantitative PCR. The mRNA levels were normalised to the internal
reference GAPDH and to the corresponding mRNA levels of cells incubated at 37 °C (set
to 1). Error bars: mean±SEM, n=5.
428 V. Ortner et al. / Journal of Controlled Release 158 (2012) 424–432promoter. 24–48 hours after heat treatment Hsp72 mRNA returned to
basal levels, indicating a normalisation of the cellular stress response.
In summary, the artiﬁcial promoter showed similar kinetics as the
natural heat shock promoter and the peak activity of gene expression
can be modulated by adjusting duration of the applied heat stress.Fig. 4. AMF-induced regulated gene expression. (a) Effects of increasing nanoparticle
concentrations. HEK293-C5 cells mixed with no, 0.3, 0.5, 0.8 or 1% (w/v) magnetic
nanoparticles (SIGMA) were exposed to an AMF of 60 kHz and 27 A for 30 min (grey
bars). As a positive control, cells were incubated for 45 min at 43 °C (black bars).
Cells incubated at 37 °C were used as negative control (white bars). 6 hours after treat-
ment, cells were lysed and the luciferase activity was measured. The graph shows the
RLU of one representative experiment; the luciferase activity measured for the positive
control of 0.5% nanoparticles was set 100%. Variation of magnetic ﬁeld strength is
shown in (b). HEK293-C5 cells mixed with 0.5% magnetic nanoparticles (SIGMA)
were exposed for 30 min to an AMF of 60 kHz and 17–27 A, resulting in different
ﬁeld strengths. As positive control for luciferase expression (set as 100%), cells were in-
cubated for 45 min at 43 °C (black bar). Cells incubated at 37 °C were used as negative
control. 6 hours after induction, the cells were lysed and the luciferase activity was
measured. Error bars: mean±SEM, n=5. Variation of exposure times is shown in
(c). HEK293-C5 cells with 0.5% magnetic nanoparticles (SIGMA) were exposed for
1.8 min to 60 min to a magnetic ﬁeld at 60 kHz and 23 A. As positive control for lucif-
erase expression (set as 100%), cells were incubated for 45 min at 43 °C (black bar).
Cells incubated at 37 °C were used as negative control. 6 hours after induction, the
cells were lysed and the luciferase activity was measured and calculated as % of maxi-
mal activation at 43 °C. Error bars: mean±SEM, n=5.3.3. Regulation of expression by NPs and AMF treatment
The next step was to demonstrate magnetic NP-mediated activation
of non-encapsulated HEK293-C5 cells. Preliminary experiments with
NPs alone indicated an optimal heat response at an AMF of 60 kHz and
27 A. Since the induced temperature was shown to be directly linked
to the concentration of NPs (Supplementary Figure S1), substantial
differences in promoter activity were observed in dependence of the
concentration of NPs (Fig. 4a, 0.3%–1%). Cells without NPs showed no
increase in luciferase expression after magnetic ﬁeld treatment, but
reacted to incubation at 43 °C (black bars). Addition of 0.3% NPs
enhanced heat-induced expression levels in HEK293-C5 cells and
maximal luciferase activity was detected for 0.5% NPs in the AMF-
treated cells (Fig. 4a, grey bars). This resulted in a more than 100-fold
activation of the promoter (as compared to basal luciferase activity
levels in AMF-treated cells without NPs). In the presence of 0.8%–1%
NPs the luciferase levels decreased (Fig. 4a), which is most likely due
to overheating resulting in a partial cell death. According to these
results, a concentration of 0.5% magnetic NPs was chosen for further
experiments.
The possibility to activate a promoter from outside a cell or even a
human body is a major step towards a dosage-dependent expression
of therapeutic genes. A further improvement above a simple on/off
regulation would however be a ﬁne tuned modulation of promoter
activity over a wide range, enabling precise control of therapeutic
protein delivery. This would allow even highly toxic proteins with a
small therapeutic window to be considered for cell therapy
applications. We therefore tested the effects of magnetic ﬁeld strength
variation by increasing the current from 17 to 27 A (Fig. 4b). The resultsrevealed a continuous increase of promoter activity overmore than two
orders of magnitude in correspondence with the enhanced strength of
the magnetic ﬁeld.
Fig. 5. Biocompatibility of co-encapsulated magnetic NPs. HEK293-C5 cells were encap-
sulated without (a) or with 0.5% NPs S8 (b) and further cultivated. Pictures were taken
at the day of encapsulation. (c) Encapsulated cells were cultivated for a period of
28 days and their metabolic activity was monitored over time. Therefore, samples
were taken from the culture at day 4, day 11, day 18 and day 28 post encapsulation
and equivalents of cell numbers (per capsule) were calculated by means of an Alamar-
Blue assay. (d–g) To determine the localisation of co-encapsulated NPs, capsules were
analysed by electron microscopy. Samples were taken 18 days post encapsulation,
ﬁxed and embedded. 100 nm sections of encapsulated cells without NPs (d, e) or of
cells co-encapsulated with S8 NPs (f, g) were analysed (N: nucleus, M: mitochondria,
NP: nanoparticles). The membrane of one selected cell is indicated by a dotted line
(d, f). Sections of the capsule membranes are shown in e and g. (a, b) Scale
bar=700 μm, (d–g) scale bar=5 μm.
429V. Ortner et al. / Journal of Controlled Release 158 (2012) 424–432A different option to modulate promoter activity in the established
system is given by the duration of the treatment, i.e., AMF exposure.
In order to evaluate this parameter, cells mixed with 0.5% NPs were
subjected to an AMF of 60 kHz and 23 A for different time spans (1.8
to 60 min). A reduced current of 23 A was chosen to enable survival of
the cells even at prolonged exposure times. Analysis of luciferase
activity revealed a highly modulatable expression (more than three
logs) in dependence of exposure time (Fig. 4c). These experiments
demonstrate that two independent modes of control may be applied
to effectively regulate HSE promoter activity.
3.4. Co-encapsulation of cells and NPs
As mentioned previously, magnetic NPs are used for a wide range of
applications [15–18,30]. However, it has been suggested that non-coated
magnetic iron oxide NPs are toxic, which might affect the viability of
exposed cells [31,32]. For the presented approach therefore a panel of
magnetic NPs was evaluated, coated with different polymers, such as
polyethylenimine (Supplementary Table S1). The coating stabilises the
particles against rapid degradation and aggregation. The particles used
here were highly compatible with cell viability. For the proposed
application heat induction capabilities were a major criterion.
Accordingly, NPs S8,which showed the strongest increase in temperature
in response to AMF treatment (Table S1), were chosen to establish co-
encapsulation with the stably transfected HEK293 cell clone.
Co-encapsulation of cells with the selected NPs was established by
modiﬁcation of a standard procedure previously applied to encapsu-
late HEK293 cells into sodium cellulose sulphate (SCS) [3]. Due to
the increased viscosity of the SCS-cell mixture now supplemented
with 0.5% NPs, the concentration of SCS had to be reduced to 1.6%.
This facilitated generation of a vibration-induced stable chain of
droplets in the capsule formation process. The encapsulation mixture
was dropped into a bath containing 1.3% of the counter ion (pDAD-
MAC), with high voltage applied on an electrode. After a short gelling
phase of 3 min the microcapsules were generated by hydrogel
formation. The capsules were equally sized with a diameter of 700 μm
and contained on average 600 cells per microsphere (Fig. 5a, b).
In order to further characterise the generated capsules, the internal
localisation of encapsulated NPs was determined. To this aim, capsules
containing cells and S8 NPs, as well as capsules containing cells only,
were cultivated for two weeks to allow cell proliferation and were
subsequently subjected to transmission electron microscopy (TEM).
Uranyl-acetate-stained ultra thin sections revealed a dispersed distribu-
tion of the NPs within the membrane of the microcapsules (Fig. 5g),
indicating that the level of aggregation was low during the encapsula-
tion process. However, small aggregates of NPs were detected in the
lumen of the microcapsules (Fig. 5f), most probably originating from
the maturation process. The localization of the S8 NPs was mainly
found within the cells (Fig. 5f). This is in good agreement with their
polyethyleneimine coating, which has been shown previously to
mediate polymer-assisted, magnetic-force enhanced transfer of nucleic
acids into cells (magnetofection) [33].
3.5. Biocompatibility of magnetic NPs
To determine biocompatibility of the selected S8 NPs in detail,
generated capsules were cultured for four weeks and the number of
encapsulated cells monitored over time by determining their metabolic
activity. For comparison, cells encapsulatedwithout the addition of NPs
were analysed as well. Four days after encapsulation, in average 1000
viable cells were determined in either capsules containing or lacking
NPs. The encapsulated cells then started to divide, resulting in a
continuously increasing cell number. Analysis revealed a slightly
decreased metabolic activity of cells co-encapsulated with NPs until day
11 post encapsulation, which fully recovered after day 18 (Fig. 5c). Thus
the presence of S8 NPs might initially retard cell proliferation, which ishowever compensated during cultivation of capsules for a period of four
weeks.
Effects of magnetic-ﬁeld treatment on cells co-encapsulated with
NPs compared to those encapsulated without, were ﬁrst analysed by
histological examinations. Capsules that had been cultivated for two
weeks were exposed to an AMF generated with 60 kHz and 27 A for
30 min and subsequently further cultivated for 8 days. Samples were
taken immediately before treatment (day 0), as well as 2, 5 and 8 days
post treatment,ﬁxed in formalin and embedded in parafﬁn. Histological
sections were prepared and stained with haematoxylin and eosin
(Fig. 6). Microscopic analysis of capsules lacking NPs (Fig. 6 a–d) as
well as AMF-treated capsules containing S8 NPs (Fig. 6 e–h) revealed
the presence of a dense network of cells. Only few cells were showing
aberrant nuclei (arrows) indicating necrotic cell death, which did not
signiﬁcantly increasewith time (compare day 0, day 2, day 5 and day 8).
Next, the presence of apoptotic cells was analysed by staining the
prepared sections applying a TUNEL assay (Fig. 7). At all time points
after AMF treatment only few cells were detected that exhibited
Fig. 6. Cytological analysis of AMF-exposed encapsulated cells. HEK293-C5 cells were
encapsulated without (a–d) or in the presence of 0.5% S8 NPs (e–h) and subjected to
AMF treatment. Samples were taken before (day 0), 2 days (day 2), 5 days (day 5)
and 8 days (day 8) after magnetic ﬁeld treatment, ﬁxed and embedded in parafﬁn.
3 μm thick sections were prepared and stained with hematoxylin and eosin. Aberrant
nuclei are marked with an arrow (scale bar 25 μm).
Fig. 7. Analysis of apoptosis in AMF-treated encapsulated cells. HEK293-C5 cells were
encapsulated without (a, b, e, f, i, j, m and n) or in the presence of 0.5% S8 NPs (c, d,
g, h, k, l, o, p, s and t) and subjected to AMF treatment. Samples were taken before
(day 0), 2 days (day 2), 5 days (day 5) and 8 days (day 8) after magnetic ﬁeld treat-
ment, ﬁxed and embedded in parafﬁn. Sections were analysed by applying a TUNEL
assay, revealing the presence of fragmented DNA as a red ﬂuorescent staining (rhoda-
mine). As control, total DNA was also stained (DAPI). DNaseI-treated sections served as
positive control (q, r). Speciﬁcity of detection was shown by omitting digoxygenin-
labelled nucleotides in the reaction (negative control: s, t).
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the previous ﬁnding (Fig. 6), no signiﬁcant differences were observed
in samples co-encapsulated with NPs (Fig. 7 d, h, l and p) compared to
capsules containing cells only (Fig. 7 b, f, j and n). In addition, no sig-
niﬁcant increase in the number of apoptotic cells was observed when
samples obtained before treatment (day 0) were compared to those
after AMF treatment.
Heat formation of the NPs strongly depends on their concentration
(see Supplementary Figure S1). This might result in local overheating
in cases of aggregated particles and the TEM data indeed indicate
some aggregation (Fig. 5f). However, both the cytological analysis as
well as the apoptosis assay show that even if localised heat formation
might kill individual cells, the neighbouring cells rapidly compensate
for this cell death. In summary, the different analyses revealed that
co-encapsulation of 0.5% S8 NPs is well tolerated by HEK293 cells.
Neither proliferation nor viability appeared to be signiﬁcantly affected.
Most importantly, excitation of NPs by exposing capsules to an AMF
for 30 min did not result in increased levels of cell death demonstrating
applicability of the proposed system.
3.6. NP-mediated, AMF-induced gene expression in encapsulated cells
Having demonstrated biocompatibility of NPs subjected to AMF
treatment for encapsulated cells, the next question was whether
they would produce sufﬁcient heat to activate the inducible promot-
er. In order to provide a proof-of-principle, heat-inducible HEK293-C5
cells were co-encapsulated with magnetic S8 NPs (0.5% w/v). As a
control, the HEK293-C5 cells were also encapsulated without the
addition of NPs. Further, HEK293 cells stably transfected with either
pCMVluc or pCMVgfp and therefore constitutively expressing luciferase
or GFP were encapsulated as well. The generated capsules were then
either subjected to magnetic ﬁeld treatment (60 kHz, 27 A) for
30 min, incubated at 43 °C for 45 min (heat induction) or incubated at
37 °C (control). Subsequently, either luciferase activity was determined
(Fig. 8a) or GFP expression was analysed by FACS (Fig. 8b).
Heat treatment at 43 °C resulted in a robust induction of luciferase
(Fig. 8a, black bars) as well as GFP expression (Fig. 8b) in capsules
both containing or lacking S8 NPs. Induction levels of luciferase
expression in comparison to controls kept at 37 °C were calculated
to be more than 4500-fold. By contrast, magnetic ﬁeld treatment
(Fig. 8a, grey bars) caused a strong induction of reporter gene
expression exclusively in capsules, which contained S8 NPs. Here, a
more than 1700-fold increase of luciferase activity was determined
in comparison to samples kept at 37 °C (Fig. 8a, C5+S8 capsules),
while capsules containing HEK293-C5 cells only (Fig. 8a, C5 capsules)
showed a 26-fold increase in luciferase expression levels. Consistently,
a more than 950-fold induction of GFP expression was calculated for C5+S8 capsules (Fig. 8b, AMF) compared to a 13-fold induction in capsules
lacking S8 NPs. The determined difference in luciferase expression is
highly signiﬁcant with a p-value of 0.029 (Mann–Whitney test). In
contrast to HEK293-C5 cells, reporter gene expression of pCMVluc-
(Fig. 8a) and pCMVgfp-transfected cells (Fig. 8b) was neither inﬂuenced
by magnetic ﬁeld treatment nor by incubation at 43 °C. In conclusion, in
the presence of magnetic NPs, exposure of encapsulated HEK293-C5
cells to an AMF resulted in a signiﬁcant induction of luciferase and GFP
expression, both driven by the artiﬁcial bidirectional heat-inducible
promoter. The coil heats up substantially during operation. Due to its
small dimensions, it was not possible to completely shield the treated
capsules from heating.
4. Discussion
Encapsulation of cells is a promising technique for cell therapy appli-
cations. In particular geneticallymodiﬁed heterologous cells can thus be
protected from the immune system of the host [3,34]. The cells can
extensively be selected and tested in cell culture and therefore are
optimised for expression of a therapeutic protein. Basically all kinds of
proteins and peptides can be produced by the transplanted cells [3].
Potential applications for cell therapy so far mainly comprise replace-
ment strategies, which seek to compensate for gene deﬁciencies, yet a
ﬁne-tuned interference with genetic and biochemical pathways would
open many other ﬁelds of applications. Critical regulatory constraints
apply for example to hormones [35] or growth factors [36–38]. Similarly,
expression of the pain alleviating proopiomelanocortin encoding gene
ideally should be controlled in real-time by the patient [39]. Thus,
promoters facilitating inducible rather than constitutive expression of
therapeutic genes and, moreover, the possibility to control gene
expression from outside a patient's body, would be of great advantage.
In our concept, heat shock promoters are applied representing a
one-component inducible expression system. Two-component
Fig. 8. Nanoparticle-mediated, AMF-induced gene expression in encapsulated cells.
HEK293-C5 cells were encapsulated without (C5 caps.) or in the presence of 0.5% S8
NPs (C5+S8 caps.) and either exposed to an alternating magnetic ﬁeld (grey bars),
heat-treated by incubation at 43 °C (black bars) or kept as control at 37 °C (white
bars). In addition, encapsulated constitutively luciferase-expressing HEK293 cells
(pCMVluc caps.) were also analysed. (a) Luciferase activity was determined 6 hours
after treatment in total protein extracts prepared from the different samples. Relative
values are indicated, the luciferase activity of cells kept at 37 °C was set to 1 (statistical
signiﬁcance p=0.029, Mann–Whitney test, n=5). (b) Quantitative ﬂow cytometry
analysis was performed 24 hours after treatment with cells that have been released
from capsules. GFP ﬂuorescence blots are shown from one representative experiment
(x-axis FL1-H GFP ﬂuorescence intensity, y-axis FL2-H; gates were set according to
the controls). As controls HEK293 pCMVluc-transfected (negative) or pCMVgfp-
transfected cells were used (absolute levels of luc activity were roughly 10-fold higher
for CMV-luc-transfected compared to HEK293-C5 cells).
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exhibit a number of disadvantages for gene and cell therapy. Two-
component systems use modiﬁed transcription factors which evoke
an interfering immune response. Mostly these promoters are induced
by small molecules, which reach their targets by diffusion and as such
show slow pharmacokinetics. The TetR system, for example, was
shown to facilitate inducible gene expression in encapsulated myo-
blasts that had been implanted into mice; however, it took several
weeks to switch between the on and the off state of the promoter
[40]. Furthermore, the inducermolecules are often themselves pharma-
cologically active and cross-react with other biological pathways [41].
Heat shock promoters in contrast use endogenous pathways and
transcription factors and lack the above mentioned disadvantages of
two-component systems. Heat shock promoters such as the HSP70
promoter have therefore repeatedly been used for gene therapy
applications [42]. However, in addition to HSF1-mediated activity,
natural promoters integrate multiple cellular emergency pathways
and usually show a high background activity as well as tissue-
speciﬁc variations. To overcome this problem, an artiﬁcial heat
shock promoter built from multiple high afﬁnity HSEs linked to a
minimal CMV promoter element [21] was used in the presented
study. Reporter gene expression driven by this artiﬁcial promoter in
the generated HEK293 cell line was shown to be induced several
1000-fold by heat treatment, while exhibiting an extremely low
background activity in the uninduced state (see Fig. 3A).Temperature represents a well controllable physical parameter. The
almost uniform temperature of mammals makes localised overheating
an ideal tool to regulate gene expression. Several methods have been
established to induce such a local hyperthermia in patients. The basis
for these developments is the favourable combination of hyperthermia
with radiotherapy or chemotherapy for the treatment of tumours [15].
For superﬁcial hyperthermia, simple water baths or electromagnetic
applicators emitting microwaves are suitable [43]. More demanding is
a non-superﬁcial heat production. Focused ultrasound has been demon-
strated to induce small,well deﬁned temperature peaks deepwithin the
patients tissue [42]. This method has also been applied for activation of
HSP70 promoters in gene therapy experiments [44]. Recently, another
approach was introduced using magnetic NPs, activated by an AMF
(reviewed in Ref. [45]). After injection of NPs, magnetic hyperthermia
can precisely be induced by hysteresis heatingwithin the tumour tissue
[11], demonstrating the feasibility of such nanotechnology-based
therapies.
In our approach, as a result of co-encapsulation, NPs and therefore
also hyperthermia, are restricted to the expressing cells. We showed
that when suspended with cells, the magnetic particles were biocom-
patible with the cells and also allowed a precise control of heat shock
promoter activity over a wide range of expression (see Fig. 4). In
particular, we were able to demonstrate regulation of promoter
activity by varying either the magnetic ﬁeld strength or the time of
activation. In both cases, a control over several orders of magnitude
was possible. Most importantly, this regulation worked within
minutes, strongly contrasting the above mentioned two component
systems activated by small molecules. Therefore, inducible gene
expression mediated by magnetic NPs and an AMF is exceptional
among the available inducible expression systems for therapeutic
purposes.
The NPs at the applied concentration showed excellent biocompati-
bility both with and without AMF treatment. The AMF induced strong
expression of the respective marker proteins in the encapsulated cells,
providing a proof-of-principle for the concept. Currently, several clinical
trials using modiﬁed encapsulated cells are in progress (reviewed in
Ref. [46,47]). A next step for the establishment of our proposed
therapeutic system would include in vivo experiments with larger,
commercially available magnetic ﬁeld generators. With respect to
clinical applications, the company MagForce Nanotechnology AG in
June 2010 received EU-wide regulatory approval for utilisation of their
NPs and magnetic ﬁeld generators for hyperthermia treatment of
brain tumours. Consequently, magnetic ﬁeld generators for treatment
of patients will be available in the future allowing further evaluation
of the novel cell therapy concept presented in this study.
5. Conclusion
Biologicals represent an indispensable part of modern medicine. A
production of these molecules within the patient offers a number of
advantages, in particular the concentrated expression directly in the
affected tissues or organs. Cell therapywith encapsulated cells provides
a solution for such a treatment. In order to enable dosage control we
developed a method for regulated gene expression in encapsulated
cells.
The presentedmethod combines magnetic nanoparticles with a heat
inducible promoter. An alternating magnetic ﬁeld selectively activates
the nanoparticles. This combination works highly efﬁcient and allows a
ﬁne tuned regulation of gene expression over a broad range. Compared
to other inducible systems the modulation of the expression by the
magnetic ﬁeld is fast and reproducible. The produced heat remains
concentrated to the capsules, not affecting the surrounding tissue and
is readily tolerated by the transplanted cells. Taken together our method
allows the dose dependent application of biologicals by cell therapy.
Supplementary materials related to this article can be found
online at doi:10.1016/j.jconrel.2011.12.006.
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